Tramiprosate (Alzhemed™) preclinical results published in Neurobiology of Aging
Tramiprosate (Alzhemed) shows promising results by binding to soluble Aβ peptide, reducing cell death and plasma Aβ levels. The compound also demonstrates low toxicity while crossing the blood-brain-barrier.